MARKET

PLX

PLX

PROTALIX BIOTHER
AMEX

Real-time Quotes | Nasdaq Last Sale

4.900
+0.070
+1.45%
After Hours: 4.880 -0.02 -0.41% 19:55 02/26 EST
OPEN
5.00
PREV CLOSE
4.830
HIGH
5.04
LOW
4.700
VOLUME
752.52K
TURNOVER
--
52 WEEK HIGH
7.02
52 WEEK LOW
2.036
MARKET CAP
216.78M
P/E (TTM)
-33.2429
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Making A List Of Penny Stocks To Buy This Week? Analysts Like These 5
Feb 24, 2021 (Penny Stocks via COMTEX) -- 5 Penny Stocks To Buy According To These 4 Analysts I know it's the weekend of the Big Game, and you may be...
Penny Stocks · 2d ago
PLX: A Busy Month
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Over the last few weeks, Protalix Biotherapeutics, Inc. (NYSE:PLX) has posted several updates includ-ing the announcement of pricing and closing of its ~$40 million financing. The company...
Zacks Small Cap Research · 2d ago
Thinking about buying stock in Vascular Biogenics, Oncolytics Biotech, Protalix Biotherapeutics, AMC Entertainment, or Applied DNA Sciences?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VBLT, ONCY, PLX, AMC, and APDN.
PR Newswire - PRF · 3d ago
VET, TCOM, TTM and ZI among premarket gainers
Yunhong CTI (CTIB) +77%.Dawson Geophysical (DWSN) +39%.ReTo Eco-Solutions (RETO) +31%.Vascular Biogenics (VBLT) +29%.Vinco Ventures (BBIG) +35%.Sunesis Pharmaceuticals (SNSS) +12%.Oncolytics Biotech (ONCY) +11% on encouraging pelareorep + CAR T data in sol...
Seekingalpha · 3d ago
Protalix's PRX–102 Monthly Treatment Shows Benefit In Fabry Disease
Benzinga · 3d ago
Protalix Bio up 6% on positive PRX–102 data in Fabry disease
Protalix BioTherapeutics (PLX) and Chiesi Farmaceutici S.p.A., have announced positive topline results from the BRIGHT Phase III trial evaluating pegunigalsidase alfa (PRX–102), 2 mg/kg, for the potential treatment of Fabry disease.Topline results
Seekingalpha · 3d ago
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 3d ago
8-K: Protalix BioTherapeutics, Inc.
(EDGAR Online via COMTEX) -- 0001006281false00010062812021-02-232021-02-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLX. Analyze the recent business situations of PROTALIX BIOTHER through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLX stock price target is 13.00 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 12.41M
% Owned: 28.06%
Shares Outstanding: 44.24M
TypeInstitutionsShares
Increased
6
1.51M
New
7
1.67M
Decreased
3
89.21K
Sold Out
9
231.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
Zeev Bronfeld
President/Chief Executive Officer/Director
.. ..
President/Chief Executive Officer/Director
Dror Bashan
Chief Financial Officer/Senior Vice President
Eyal Rubin
Senior Vice President
Einat Almon
Senior Vice President
Yaron Naos
Vice President - Research & Development
Yael Hayon
Director
Pol Boudes
Director
Gwen Melincoff
Independent Director
Amos Bar-Shalev
Independent Director
David Granot
Independent Director
Aharon Schwartz
  • Dividends
  • Splits
  • Insider Activity
No Data
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Webull offers kinds of Protalix Biotherapeutics Inc stock information, including AMEX:PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.